<DOC>
	<DOC>NCT01428986</DOC>
	<brief_summary>This study is to investigate the safety of maraviroc by examining whether there is bone metabolism dysfunction in actual use of maraviroc in human body, or not, measuring bone mineral density and markers for bone formation, desorption and chemokine.</brief_summary>
	<brief_title>Safety Study of Maraviroc's Effect on Human Osteoclasts</brief_title>
	<detailed_description>An observational study to investigate the safety of maraviroc by examining whether there is bone metabolism dysfunction in actual use of maraviroc in human body, or not, measuring bone mineral density and markers for bone formation, desorption and chemokine.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Outpatients or inpatients that are treated for HIV infection at AIDS Clinical Center of National Center for Global Health and Medicine who meet all criteria following: Those whose primary care physician acknowledged the necessity of maraviroc treatment due to multiresistance HIV strain that is confirmed to have CCR5 tropism. Those who are willing and able to consent to this study 20 years old or older Cases applicable to ANY condition of the following: Those who are not suited for maraviroc (whose HIV strain to be CXCR4 tropism) Others who the principle investigator physician considered to be excluded</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>maraviroc</keyword>
	<keyword>osteoclasts</keyword>
	<keyword>Receptors, CCR5</keyword>
	<keyword>Chemokine CCL5</keyword>
</DOC>